Lilly invests in epigenetic reprogramming biotech
NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…
Is Altos Labs gearing up for clinical trials?
Appointment of Joan Mannick as CMO is a sign that company’s cellular rejuvenation programs may be nearing readiness…